Meet Pharmidex at KTN 2016
June 14, 2016

Collaboration opportunities in regenerative medicine

Pharmdiex will be attending the Innvoate UK KTN 2016 meeting focused on New Collaboration Opportunities in Regenerative Medicine.

The KTN in collaboration with Innovate UK, Cell and Gene Therapy Catapult, Department of Health and Kings College London are holding an event focussing on new unmet clinical needs, latest developments in regulatory environment and clinical adoption. Following recent developments and the UK’s Regenerative Medicine Expert Group report recommendations, this event will bring together the UK regenerative medicine communities involving industrialists, academics and clinicians from a number of clinical specialities.


The UK is leading the field in the development of cell and gene therapies. The regulatory system now has a number of mechanisms to accelerate the progress of promising therapies including EAMS and the proposed new PRIME scheme. However, practical challenges still exist to the clinical adoption of these new therapies and getting them to patients, including generating sufficient clinical data, achieving reimbursement and embedding therapies in existing or new clinical pathways).


Leading clinicians and experts from a number of organisations will be presenting at this event. Directors and managers from major funding organisations, e.g. Innovate UK, Research Councils, relevant charities will also be invited to support this event.


The main aims of this event are as follows;


  • To discuss challenges affecting clinical adoption of cell and gene-based therapies.
  • Facilitate new clinician/industry collaborations in a number of areas of clinical specialities.
  • Identify barriers to innovation and commercialisation.
  • Review current funding opportunities and identify funding gaps.
  • Provide networking opportunities to identify collaborating partners.
  • Review supporting mechanisms available to accelerate innovation and commercialisation through KTN and partners Innovate UK, Cell and Gene Therapy Catapult organisations.
  • Review current pre-clinical and clinical trials and identify best practice to accelerate regulatory approvals


For more information please see the following link: https://www.eventbrite.co.uk/e/new-collaboration-opportunities-in-regenerative-medicine-tickets-24454460951

November 19, 2025
The Pharmidex team will be in London for London Life Sciences Week from the 16th. Janette Dalay Robertson and Ash Alavijeh will be attending a range of events across the week. We are looking forward to a busy week discussing all things life-science related. Get in touch if you’d like to meet with us during the week as we visit existing clients and stakeholders!
November 12, 2025
Our Head of Integrated Therapeutics and CNS, Dr. Stephen Mitchell , our Business Development Manager, Janette Dalay Robertson and our Senior Research Scientist in CNS, Jewel Ahmed will be there to engage with attendees, share insights and explore new collaborations driving innovation in Parkinson’s disease drug discovery and development. If you’re attending, don’t hesitate to reach out, they’ll be delighted to connect and discuss how Pharmidex’s integrated expertise can help move your research from concept to clinic.
November 11, 2025
We are delighted to share that Prof. Mo Alavijeh will be attending the upcoming 🔬 OBN (UK) Ltd BioTuesday: A Spotlight on the Latest R&D for the Diagnosis & Treatment of Prostate Cancer 📅 11 November 2025 📍 Ipsen, Paddington, London This event brings together leading experts and innovators shaping the future of prostate cancer research and therapy. If you’re attending, don’t miss the opportunity to meet with Prof. Mo Alavijeh (FRSC, FRSM), and explore how collaboration can accelerate progress in drug discovery and development.
More Posts